Metformin blunted exercise-induced improvements in vascular insulin sensitivity, aerobic fitness, inflammatory markers, and fasting glucose levels in adults at high risk for metabolic syndrome, ...
A phase 3 trial found that metformin did not delay disease progression in men with low-risk prostate cancer on active surveillance. However, it did significantly increase the risk for pathologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback